Ladera Medical Unveils Enhanced Hemostasis Results from FASTEN Trial with New Closure System

Ladera Medical Unveils Enhanced Hemostasis Results from FASTEN Trial with New Closure System



Ladera Medical recently disclosed the full outcomes of its groundbreaking FASTEN clinical trial, centered around the Ladera Large Bore Closure System. This innovative device aims to streamline the closure process following transfemoral transcatheter aortic valve replacement (TAVR) or implantation (TAVI) procedures. The impressive results were presented by Dr. Jan van der Heyden, an Interventional Cardiologist at St. Jan Hospital in Bruges, Belgium, during a key session at London Valves 2026.

In this multicenter clinical study, 55 patients participated across six locations in Australia, Belgium, and the Netherlands. The primary safety endpoint was assessed over a 30-day period, where the system demonstrated a remarkable 98.1% freedom from significant access-site complications. Additionally, the mean time to hemostasis was recorded at a swift 0.5 ± 2.0 minutes, with most patients achieving this in under a minute. Further investigation into secondary endpoints revealed a technical success rate of 94.5%, with 94.3% of treatments achieving successful outcomes without major complications.

Dr. van der Heyden emphasized the practicality of the suture-based closure system, commenting, "This device is intuitive for operators to use, whether applied before or after the procedure. Maintaining guidewire access throughout the closure process provides an essential safety net for unforeseen complications." This innovation is particularly relevant as the TAVI/TAVR landscape experiences rapid growth, increasing the demand for effective closure solutions as large bore transcatheter approaches become more common.

Despite the evolving techniques in TAVR/TAVI, access site closure is frequently complicated by issues including bleeding and vascular injuries, which may extend hospitalization durations. Associate Professor Robert Gooley from Monash Health in Melbourne concurs, stating, "In the current medical landscape, large bore access presents unique challenges. Existing methods, whether employing multiple small-bore devices or materials left inside arteries, have shown limitations, reinforcing the need for a dedicated solution like the Ladera system."

The Ladera Closure System is the first of its kind designed specifically for large bore arteriotomies (ranging from 10F to 24F), capable of achieving secure closure with just one device. Suture-based techniques remain the gold standard, as they effectively prevent major intravascular implants that could hinder future access. Besides its unique dual-suture mechanism, this innovative system allows operators to deliver the sutures either before or after the procedure while simultaneously ensuring guidewire access is preserved.

As Ladera Medical continues to refine the Large Bore Closure System, it remains focused on ensuring safe, reliable closure solutions for patients undergoing large bore cardiovascular interventions. Currently, the Ladera LBC System is categorized as investigational and is not yet available for commercial distribution.

In closing, Ladera Medical is at the forefront of transforming cardiovascular care with their innovative approaches, reinforcing their commitment to improving patient outcomes and enhancing procedural efficiencies in the rapidly evolving landscape of interventional cardiology. For more information on their products and trials, visit laderamedical.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.